Quoin pharmaceuticals poised for rapid commercialization of promising pipeline

New york, new york--(newsfile corp. - november 16, 2021) - pcg digital -- following a successful merger, one firm is developing and commercializing therapies for rare skin conditions. quoin pharmaceuticals (nasdaq: qnrx) is positioned to deliver the first fda-approved treatment for netherton syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide.key takeawaysquoin recently completed a successful merger with cellect biotechnology ltd. and is now trading on the nasdaq capital market (nasdaq: qnrx).the company has a...
QNRX Ratings Summary
QNRX Quant Ranking